Acute Effect of a GLP-1-Analogue (Exenatide) and of a DPP-4-Inhibitor (Sitagliptin) in Subjects With Type 2 Diabetes Treated With Insulin Glargine Once Daily

NCT00971659 Phase 1 COMPLETED

This study investigated a 4-week adjunctive therapy of either a GLP-1 analog (exenatide), or a DPP-4 inhibitor (sitagliptin), given to a basal insulin analog (insulin glargine), and their effect on blood glucose control, versus insulin glargine alone as active comparator in type 2 diabetes.

Details

Lead sponsor	Profil Institut für Stoffwechselforschung GmbH
Phase	Phase 1
Status	COMPLETED
Enrolment	48
Start date	2008-01
Completion	2008-11

Conditions

• Type 2 Diabetes

Interventions

• insulin glargine + exenatide + preexisting metformin
• insulin glargine + sitagliptin + preexisting metformin
• insulin glargine + preexisting metformin

Primary outcomes

• the unadjusted 6-hour postprandial blood glucose excursion (AUCBG0-6h) following ingestion of a standardized breakfast — after 4 weeks of treatment

Countries

Germany